The London-based energy management platform raised the capital from Cambridge Enterprise Ventures, Cambridge Angels, Parkwalk, and R42 to scale its product development.
"Our mission is straightforward but ambitious: to decarbonise the world’s most complex real estate in a way that is intelligent, automated and scalable. We don’t just tell you what to do, we do it for you. This funding allows us to double down on the growth and product investment needed to compete at scale."
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
The seed round was led by the UK Innovation & Science Seed Fund to support team expansion and product development.
"X-ray scanners are such a common technology that we don’t often think of them as an area for innovation. But the reality is that the addressable market is huge – far beyond the obvious medical applications, with X-ray equipment critical in a range of sectors from construction to manufacturing. Silveray’s technology could play a key role in bringing the world’s oldest imaging technology into the 21st century."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
